Sector News

Cardinal Health nears $6 billion deal for Medtronic unit: Sources

April 7, 2017
Life sciences

U.S. drug distributor Cardinal Health is nearing a deal to acquire medical device maker Medtronic’s medical supplies business for close to $6 billion, people familiar with the matter said on Wednesday.

The sale would streamline Medtronic’s portfolio after its $42.9 billion acquisition of Covidien in 2014. In that deal, it inherited most of the company’s medical supplies business, which sells everything from syringes to surgical instruments.

Medtronic and Cardinal Health have entered into exclusive talks over the sale of the business, and a deal could be announced later this month, the sources said, cautioning that there was always a chance that the negotiations could end unsuccessfully.

The sources asked not to be identified because the negotiations are confidential. Medtronic and Cardinal Health declined to comment.

For Cardinal Health, the deal would boost efforts to build out its medical products business, which it has highlighted as a priority for dealmaking.

“Certainly a part of the equation for us is how we use our balance sheet, and that may be through activities that are available external to us and the other ways that we deploy capital,” George Barrett, Cardinal Health’s chief executive officer, said last month on the company’s most recent quarterly earnings call.

In 2015, Cardinal Health acquired Cordis from Johnson & Johnson for around $2 billion, adding a portfolio of devices including catheters, filters and stents.

Cardinal Health’s medical products business has been a bright spot for the company, on track to reach mid- to high-single-digit revenue growth, at a time when investors have become more anxious about its drug distribution business.

This is because the entire drug supply chain, including pharmaceutical benefits managers and drugmakers, has been under pressure in recent years, amid increasing scrutiny among lawmakers and insurance companies over high drug costs.

Cardinal Health, along with its peers McKesson and AmerisourceBergen, late last year saw their shares drop after McKesson said that competition was weighing on margins more than expected.

Cardinal Health’s share price has since recovered, despite it having lowered expectations for full-year earnings in its pharma segment.

Source: Reuters via CNBC

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).